The past year has been challenging for gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP). The company lagged the market as economic...
The past year has been challenging for gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP). The company lagged the market as economic...